We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02038972
Recruitment Status : Completed
First Posted : January 17, 2014
Last Update Posted : March 5, 2018
CBR Systems, Inc.
Information provided by (Responsible Party):
James Baumgartner, MD, AdventHealth

Brief Summary:
To determine if autologous human umbilical cord blood infusion in children with acquired hearing loss is safe, feasible, improves inner ear function, audition and language development.

Condition or disease Intervention/treatment Phase
Sensorineural Hearing Loss Genetic: Autologous Stem Cells Phase 1 Phase 2

Detailed Description:
There is currently no treatment available to repair/reverse acquired sensorineural hearing loss. Recent experiments using human umbilical cord blood treatment of a mouse and guinea pig models have demonstrated hair cell re-growth following acquired sensorineural loss as well as partial restoration of ABR. Autologous human umbilical cord blood therapy, which has been used for over twenty years, has an excellent safety record. This study will determine if autologous human umbilical cord blood infusion in children with hearing loss is safe and feasible, improves inner ear function, audition, and language development. The patients umbilical cord stem cells collected at birth and stored at Cord Blood Registry will be used for infusion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
Study Start Date : January 2013
Actual Primary Completion Date : December 11, 2015
Actual Study Completion Date : January 10, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Autologous Stem Cells
A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
Genetic: Autologous Stem Cells
The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
Other Name: Cell based therapy

Primary Outcome Measures :
  1. Safety of Autologous Stem Cell Infusion [ Time Frame: 1 year ]

    To determine if autologous human umbilical cord blood (hUBC) infusion in children with hearing loss is safe and feasible. Infusion related toxicity as measured by:

    i. hemodynamic instability: An adverse event will be defined as a sustained (> 10 minutes) >20% decrease in MAP.

    ii. acute lung injury: Chest X-ray will be done at baseline and at 1 day post infusion to assess for polymorphonuclear infiltrates iii. hepatic injury/toxicity: Hepatic panel will be performed at baseline and 1 day post infusion. Injury is defined as acute elevation of the AST/ALT hepatic enzymes > 900 U/dl in the first 24 hours post infusion iv. renal injury/insufficiency: CMP will be performed at baseline and 1 day after infusion v. exacerbation of neurological status: defined as a change in Glasgow Coma Scale, pupillary size/reactivity, motor/sensory evaluation of extremities, and seizure activity from infusion to discharge.

Secondary Outcome Measures :
  1. Inner Ear Function, Audition, and Language Development [ Time Frame: 1 year ]
    To determine if autologous hUBC transplantation in children with hearing loss improves inner ear function, audition and language development.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Weeks to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Evidence of a sensorineural hearing loss

    • Unilateral or bilateral in configuration
    • Symmetrical or asymmetrical configuration
    • Sudden or progressive in presentation
    • Moderate to profound in degree (40-90 Decibels (dB) in at least one ear
  2. Normally shaped cochlea, as determined by MRI
  3. The loss must be considered:

    • Acquired
    • Unknown with a negative genetic test.
  4. Fitted for hearing aids no later than six months post detection of loss.
  5. Enrollment in a parent/child intervention program
  6. Age 6 weeks - 6 years old at time of infusion with less than 18 months of hearing loss at the time of cord blood infusion.
  7. Ability of the child and caregiver to travel to Orlando, and stay for at least 4 days, and to return for all follow-up visits.

Exclusion Criteria

  1. Inability to obtain all pertinent medical records:

    • (pertinent physician notes, speech language pathology notes, laboratory findings, test results and imaging studies-must be sent to the research team at least prior to the subject arriving at the study location for preliminary screening and eligibility assessment, preferably14 days before the scheduled hUBC treatment.)
  2. Known history of:

    • Recently treated infection less than 2 weeks before infusion.
    • Renal disease of altered renal function as defined by serum creatinine > 1.5 mg/dl at admission.
    • Hepatic disease or altered liver function as defined by SGPT > 150 U/L, and or T. Bilirubin > 1.3 mg/dL
    • Malignancy
    • Immunosuppression as defined by WBC < 3,000 at admission
    • Human Immunodeficiency Virus (HIV)
    • Hepatitis B
    • Hepatitis C
    • Evidence of an extensive stroke (> 100ml lesion)
    • Pneumonia, or chronic lung disease requiring oxygen
    • Genetic syndromic sensorineural hearing loss
  3. hUBC sample contamination
  4. Banked cord cells totaling less than 6x106 mononuclear cells/kilogram body weight.
  5. Evidence of the following maternal infections during the pregnancy (Hepatitis A, Hepatitis B, Hepatitis C, HIV 1, HIV 2, Human T-lymphotropic Virus (HTLV) 1, HTLV 2 (CMV and Syphilis can be included in the study)
  6. participation in a concurrent intervention study
  7. Unwillingness or inability to stay for 4 days following hUBC infusion (should problems arise following the infusion) and to return for the one month, six month and one year follow-up visits.
  8. Presence of a cochlear implantation device
  9. Evidence of a genetic syndrome
  10. Evidence of conductive hearing loss
  11. Documented recurrent middle ear infections which are frequent (>5 per year)
  12. Otitis media at the time of examination
  13. Sensorineural loss is mild
  14. Over 18 months from identification of hearing loss at time of infusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02038972

Layout table for location information
United States, Florida
Florida Hospital
Orlando, Florida, United States, 32803
Sponsors and Collaborators
James Baumgartner, MD
CBR Systems, Inc.
Layout table for investigator information
Principal Investigator: James Baumgartner, MD AdventHealth
Layout table for additonal information
Responsible Party: James Baumgartner, MD, Primary Investigator, AdventHealth
ClinicalTrials.gov Identifier: NCT02038972    
Other Study ID Numbers: 434269
First Posted: January 17, 2014    Key Record Dates
Last Update Posted: March 5, 2018
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Hearing Loss, Sensorineural
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases